From a biochemical medicinal viewpoint, Relafen 750 (naproxen sodium) represents a compelling case study in noncopyrightal anti-inflammatory drug action. Its mode of alleviating inflammation and soreness copyrights primarily on the suppression of cyclooxygenase (COX) catalysts, specifically COX-1 and COX-2. Understanding the selective features of t